The Effect of Chlorella Vulgaris Supplementation on Metabolic, Blood Pressure and Antropometric Indices on Non-alcoholic fatty liver disease (NAFLD) patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012110911220N1

Enrollment

Registered

2012-11-16

Start date

2012-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention Group: 300 mg chlorella vulgaris, 4 tablets/day for 8 weeks. Intervention 2: Placebo groups: placebo, 4 tablets/day for 8 weeks.

Treatment - Drugs

Placebo

Intervention Group: 300 mg chlorella vulgaris, 4 tablets/day for 8 weeks

Placebo groups: placebo, 4 tablets/day for 8 weeks

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Liver steatosis on sonographic image; 20-50 years old; BMI>=30; moderately activity. Exclusion criteria: Alcohol intake more than 20g/d; gestation or lactation or Menopause; very active or inpatients; Cardiovascular disease; Pulmonary disease; renal disease; liver transplantation; other liver diseases and chronic or acute liver disease(Hepatitis A,B, ...); bilious impairments; cancers; inheritance diseases; using drugs like, insulin sensitivity enhancer, hepatotoxic drugs and estrogen

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver Enzyme (ALT,AST,ALP). Timepoint: Beginning and end of the intervention. Method of measurement: IFCC.;Liver steatosis. Timepoint: Begining and end of intervention. Method of measurement: Liver Sonography.;FBS. Timepoint: Begining and end of intervention. Method of measurement: Enzymatic method.;TC, TG, LDL-C, HDL_c. Timepoint: Begining and end of intervention. Method of measurement: Enzymatic method forTC,TG and HDL-c for LDL-c:Freid wals formula.;Blood pressure. Timepoint: Begining and end of intervention. Method of measurement: Mercury manometer.;Anthropometry. Timepoint: Begining and end of intervention. Method of measurement: Scale and meter.	—

Measure

Time frame

Liver Enzyme (ALT,AST,ALP). Timepoint: Beginning and end of the intervention. Method of measurement: IFCC.;Liver steatosis. Timepoint: Begining and end of intervention. Method of measurement: Liver Sonography.;FBS. Timepoint: Begining and end of intervention. Method of measurement: Enzymatic method.;TC, TG, LDL-C, HDL_c. Timepoint: Begining and end of intervention. Method of measurement: Enzymatic method forTC,TG and HDL-c for LDL-c:Freid wals formula.;Blood pressure. Timepoint: Begining and end of intervention. Method of measurement: Mercury manometer.;Anthropometry. Timepoint: Begining and end of intervention. Method of measurement: Scale and meter.

—

Secondary

Measure	Time frame
Energy and nutrient intake. Timepoint: beginning and end of the intervention. Method of measurement: Dietary record and food frequency questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoodabeh Aliashrafi

Student Serearch Committee, Nutrition and Health faculty,Tabriz university of medical sciences

Aliashrafis@tbzmed.ac.ir ; SA.NUY89@yahoo.com ; SAliashrafi@gmail.com+98 41 1334 1113

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026